Atrion Corporation (NASDAQ:ATRI) Given Daily News Impact Score of 0.16

News stories about Atrion Corporation (NASDAQ:ATRI) have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Atrion Corporation earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 46.0013195484314 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

Separately, BidaskClub lowered shares of Atrion Corporation from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 27th.

Shares of Atrion Corporation (NASDAQ:ATRI) traded down 1.70% during mid-day trading on Friday, reaching $622.95. 2,834 shares of the company were exchanged. The stock has a market capitalization of $1.15 billion, a P/E ratio of 34.90 and a beta of 0.91. Atrion Corporation has a 12 month low of $393.95 and a 12 month high of $691.95. The firm has a 50-day moving average price of $638.50 and a 200 day moving average price of $538.15.

Atrion Corporation (NASDAQ:ATRI) last released its quarterly earnings results on Tuesday, August 8th. The medical instruments supplier reported $5.40 earnings per share for the quarter. The company had revenue of $36.16 million during the quarter. Atrion Corporation had a net margin of 22.75% and a return on equity of 18.67%. Equities research analysts anticipate that Atrion Corporation will post $9.90 EPS for the current fiscal year.

In related news, Chairman Emile A. Battat sold 721 shares of the firm’s stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $542.64, for a total transaction of $391,243.44. Following the transaction, the chairman now directly owns 152,112 shares of the company’s stock, valued at $82,542,055.68. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Emile A. Battat sold 655 shares of the firm’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $546.31, for a total transaction of $357,833.05. Following the transaction, the chairman now directly owns 151,297 shares in the company, valued at $82,655,064.07. The disclosure for this sale can be found here. Insiders have sold 3,392 shares of company stock worth $1,900,070 over the last ninety days. Insiders own 24.23% of the company’s stock.

WARNING: This piece of content was originally published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at

About Atrion Corporation

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Insider Buying and Selling by Quarter for Atrion Corporation (NASDAQ:ATRI)

Receive News & Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply